Artivion

Q2 FY2026 EarningsQ2 FY26 results beat revenue expectations at $125.8M vs. $120.0M consensus, driven by 16% YoY growth in aortic stent grafts and 19% in On-X products. Despite the top-line beat, the company reported a GAAP net loss of $(13.5)M ($ -0.28 EPS) compared to the expected $0.2M profit ($0.0025 EPS), primarily due to $11.7M in Endospan acquisition costs and an $8.0M fair value adjustment loss for Ascyrus contingent consideration. Strategic progress was marked by the acquisition of Endospan and FDA PMA approval for AMDS, though these initiatives increased debt to $363.4M.